DIA Biosimilars 2013

MacroGenics

MacroGenics, Gilead Sciences to develop four DART products

Monday, January 7, 2013 01:47 PM

MacroGenics, a privately held biotechnology company that develops next generation antibody therapeutics, has entered into a license agreement with Gilead Sciences, a biopharmaceutical company focused on unmet medical needs, for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at up to four undisclosed targets.

More... »

Cenduit: Now with Patient Reminders

MacroGenics, Servier to develop three anti-cancer DART products

Friday, September 21, 2012 11:56 AM

MacroGenics, a Rockville, Md.-based privately held biotech that develops next generation antibody therapeutics, and Servier, a privately-held French pharmaceutical company, have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.

More... »

CRF Health – eCOA Forum

MacroGenics publishes DART data

Friday, April 29, 2011 11:43 AM

MacroGenics, a biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, has published in the journal Blood preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs